

O I P E
Feb 11 2002
RECEIVED
MAIL DATE CANCELLED
O I P E
Feb 14 2002
JCA
PATENT & TRADEMARK OFFICE
RECEIVED
FEB 14 2002
160/290

FORM PTO-1449 (Modified)

O I P E
Feb 11 2002ATTY. DOCKET NO.
18025-1014SERIAL NO.
09/887,496APPLICANT
Banerjee et al.FILING DATE
June 22, 2001GROUP
1617LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUB CLASS	FILING DATE
W	A	3	9	2	9	7	6	8		12/30/75	Brattsand et al	260	239.55	05/14/73
	B	3	9	9	4	9	7	4		11/30/76	Murakami et al	260	562	05/07/74
	C	4	3	3	5	1	2	1		06/15/82	Phillipps et al	424	241	02/13/81
	D	5	0	3	3	2	5	2		07/23/91	Carter	53	425	07/30/90
	E	5	0	5	2	5	5	8		10/01/91	Carter	206	439	07/27/90
	F	5	3	2	3	9	0	7		06/28/94	Kalvelage	206	531	03/15/93
	G	5	5	2	5	6	2	3		06/11/96	Spear et al	514	423	03/11/94
	H	5	6	0	2	1	1	0		02/11/97	Drumm et al	514	47	01/26/95
	I	5	6	5	4	2	7	6		08/05/97	Barrett et al	514	13	06/07/95
	J	5	6	6	8	1	1	0		09/16/97	Barrett et al	514	13	06/07/95
	K	5	6	7	4	8	6	0		10/07/97	Carling et al	514	171	10/03/94
	L	5	6	7	7	2	8	0		10/14/97	Barrett et al	514	14	06/07/95
	M	5	6	7	7	8	0	9		10/14/97	Kadlec	360	78.09	06/01/95
	N	5	6	8	3	9	8	3		11/04/97	Barrett et al	514	12	06/07/95
	O	5	6	9	1	3	3	6		11/25/97	Dorn et al	514	236.2	09/08/95
	P	5	7	3	3	5	2	6		03/31/98	Trevino et al	424	9.52	12/14/95
	Q	5	7	5	0	5	4	9		05/12/98	Caldwell et al	514	364	10/15/96
	R	5	7	8	0	4	6	7		07/14/98	Dorn et al	514	236.2	08/08/97
	S	5	7	9	5	5	6	4		08/18/98	Aberg et al	424	45	03/07/96
	T	5	8	7	4	4	8	1		02/23/99	Weers et al	514	761	06/07/95
	U	5	8	7	7	1	9	1		03/02/99	Caldwell et al	514	337	10/22/97
	V	5	9	2	9	0	9	4		07/27/99	Durette et al	514	340	10/22/97
	W	5	9	6	5	6	2	2		10/12/99	Senanayake	514	653	06/23/98
W	X	5	9	7	2	9	1	9		10/26/99	Carling et al	514	171	10/07/97

EXAMINER


Mel R

DATE CONSIDERED

04/16/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
18025-1014SERIAL NO.
09/887,496

TECH CENTER 1600/2900

FEB 20 2002

RECEIVED

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

MAIL DATE CANCELLED

PATENT & TRADEMARK OFFICE

APPLICANT
Banerjee *et al.*FILING DATE
June 22, 2001GROUP
1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
NP	Y	6	0	0	4	5	3	7	12/21/99	Blondino <i>et al.</i>	424	45	12/18/98
	Z	6	0	4	0	3	4	4	03/21/00	Gao <i>et al.</i>	514	554	05/21/98
	AA	6	0	4	1	7	7	7	03/28/00	Faithfull <i>et al.</i>	128	200.24	12/01/95
	AB	6	0	6	8	8	3	3	05/30/00	Aberg <i>et al.</i>	424	45	08/18/98
	AC	6	0	7	1	9	7	1	06/06/00	Senanayake	514	653	05/05/99
	AD	6	1	2	6	9	1	9	10/03/00	Stefely <i>et al.</i>	424	45	02/07/97
	AE	6	1	3	6	6	0	3	10/24/00	Dean <i>et al.</i>	435	375	03/26/99
	AF	6	1	5	0	4	1	8	11/21/00	Hochrainer <i>et al.</i>	514	630	11/12/99
NB	AG	6	1	6	1	5	3	6	12/19/00	Redmon <i>et al.</i>	128	200.14	10/07/98

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No
M8	AH	2	3	0	5	0	9	2	02/02/73	Germany				
1	AI	9	9	0	0	1	3	4	07/01/99	PCT				
NB	AJ	9	9	3	6	0	9	5	22/07/99	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

M8	AK	Bartow and Brogden, "An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma," <i>Drugs</i> , 55(2):303-322 (1998)
	AL	Campbell <i>et al.</i> , "A comparison of the efficacy of long-acting B2-agonists: eformoterol via Turbohaler(R) and salmeterol via pressurized metered dose inhaler or Accuhaler (R), in mild to moderate asthmatics," <i>Respiratory Medicine</i> , 93:236-244 (1999)
	AM	Dellamary <i>et al.</i> , "Hollow Porous Particles in Metered Dose Inhalers," <i>Pharmaceutical Research</i> , 17(2):168-174 (2000)
M8	AN	Derwent# 000971705, WPI Acc. No. 1973-48969U/197335 citing German Patent Application No. DE 2305092 A, "Alpha-aminomethylbenzyl alcohol derivs. -prepd. by redn. of corresponding protected derivs."

EXAMINER


NP

DATE CONSIDERED

04/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
18025-1014SERIAL NO.
09/887,496APPLICANT
Banerjee *et al.*FILING DATE
June 22, 2001GROUP
1617LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTFEB 20 2002
RECEIVED
TECH CENTER 1600
600200

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	Ekstrom <i>et al.</i> , "Low-dose formoterol Turbuhaler(R) (Oxis(R)) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.)," <i>Respiratory Medicine</i> , <u>92</u> :1040-1045 (1998)
AP	Kaumann and Lemoine, "Direct labelling of myocardial B1-adrenoceptors; Comparison of binding affinity of 3H-(--)-bisoprolol with its blocking potency," <i>Archives of Pharmacology</i> , <u>331</u> :27-39 (1985)
AQ	Lecaillon <i>et al.</i> , "Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder Inhalation via aerolizer (TM)," <i>European Journal Clinical Pharmacology</i> , <u>55</u> :131-138 (1999)
AR	Lemoine <i>et al.</i> , "Direct labelling of B2-adrenoceptors; Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551," <i>Archives of Pharmacology</i> , <u>331</u> :40-51 (1985)
AS	Lotvall <i>et al.</i> , "Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler," <i>Can Respir J</i> , <u>6</u> (5):412-416 (1999)
AT	Nielsen <i>et al.</i> , "Flow-dependent effect of formoterol dry-powder inhaled from the Aeolizer (R)," <i>Eur Respir J</i> , <u>10</u> :2105-2109 (1997)
AU	Nightingale <i>et al.</i> , "Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma," <i>Am J Respir Crit Care Med</i> , <u>159</u> :1786-1790 (1999)
AV	Nogradi, T., (editor), <i>Medicinal Chemistry: A Biochemical Approach</i> , 388-392 (1985)
AX	Palmqvist <i>et al.</i> , "Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency," <i>Eur Respir J</i> , <u>10</u> :2484-2489 (1997)
AY	Rico-Mendez <i>et al.</i> , "Formoterol en polvo seco, dos veces al dia versus salbutamol aerosol, cuatro veces al dia, en pacientes con asma estable," <i>Revista Alergia Mexico</i> , <u>XLVI</u> (5):130-135 (1999)
AZ	Ringdal <i>et al.</i> , "Onset and duration of action of single doses of formoterol inhaled via Turbuhaler(R)," <i>Respiratory Medicine</i> , <u>92</u> :1017-1021 (1998)
BA	Schreurs <i>et al.</i> , "A dose-response study with formoterol Turbuhaler(R) as maintenance therapy in asthmatic patients," <i>Eur Respir J</i> , <u>9</u> :1678-1683 (1996)
BB	Seberova and Andersson, "Oxis(R) (formoterol given by Turbuhaler(R)) showed as rapid an onset of action as salbutamol given by a pMDI," <i>Respiratory Medicine</i> , <u>94</u> :607-611 (2000)
BC	Selroos <i>et al.</i> , "Delivery Devices for Inhaled Asthma Medication," <i>Clin Immunother</i> , <u>6</u> :273-299 (1996)

EXAMINER

DATE CONSIDERED

04/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

FEB 11 2002

ATTY. DOCKET NO.
18025-1014SERIAL NO.
09/887,496RECEIVED
FEB 20 2002
TECH CENTER 1600
2900LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
Banerjee *et al.*FILING DATE
June 22, 2001GROUP
1617

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MA	BD	Tomioka <i>et al.</i> , "Anti-Allergic Activities of the B-Adrenoceptor Stimulant Formoterol (BD 40A)," <i>Arch Int Pharmacodyn</i> , 250:279-292 (1981)
	BE	Totterman <i>et al.</i> , "Tolerability to high doses of formoterol and terbutaline via Turbuhaler(R) for 3 days in stable asthmatic patients," <i>Eur Respir J</i> , 12:573-579 (1998)
MA	BF	Ullman <i>et al.</i> , "Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study," <i>Allergy</i> , 51:745-748 (1996)

EXAMINER

24/15/02

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.